1. Generics Bulletin

IGBA Impresses Importance Of Off-Patent Industry On WHO

CEO Advisory Committee Speaks Directly With WHO Leaders At October Meeting

 
• By Dave Wallace

The IGBA’s CEO advisory committee has met with WHO leaders, including director-general Tedros Adhanom Ghebreyesus, to impress upon them the importance of the generics and biosimilars industry in global patient care and the contribution made during the COVID-19 pandemic.

Tedros Adhanom Ghebreyesus WHO
The IGBA CEO advisory committee spoke with WHO Executive Director Tedros Adhanom Ghebreyesus • Source: Shutterstock

World Health Organization leaders this week heard from top generics and biosimilars industry executives about the importance of the off-patent sector in global patient care and the contribution made by the industry during the COVID-19 pandemic, in an audience with the International Generic and Biosimilar Medicines Association’s CEO advisory committee.

The committee – which recently named Sandoz CEO Richard Saynor as its chair and Lupin CEO Vinita Gupta as vice-chair for 2023 (see sidebar) – met in person for the first time this week in Geneva, where industry representatives had what the IGBA described as “a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from Generics Bulletin

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”